Delgado VT, Carnot UJ, de Castro AR, Muñío PJ, Hernández CC, Núñez QA, Pérez RG, Rodríguez FY

Idioma: Español
Referencias bibliográficas: 35
Paginas: 231-241
Archivo PDF: 195.79 Kb.

RESUMEN

Se realizó un estudio retrospectivo-descriptivo en el Servicio de Hematología del Hospital Clinicoquirúrgico "Hermanos Ameijeiras" para conocer las causas de muerte en pacientes con diagnóstico de linfoma de Hodgkin tratados desde enero de 1983 hasta diciembre de 2008. De los 619 pacientes diagnosticados en ese período, la muestra quedó constituida por 443, de los cuales 287 (64,8 %) se encontraban vivos al final del estudio y 156 (35,2 %) habían fallecido. La recaída/progresión de la enfermedad fue la causa más importante de muerte, independientemente de la edad de presentación, la modalidad de tratamiento empleada y el tiempo de evolución (125 pacientes, 80 %). El 20 % restante de las muertes ocurrió por segundas neoplasias en 10 pacientes (6,4 %), complicaciones del tratamiento en 8 (5,1 %), complicaciones infecciosas fatales en 2 (1,2 %) y enfermedad cardiovascular en 3 (1,9 %). En 8 pacientes (5,1 %) no se precisó la causa de muerte. Las segundas neoplasias predominaron en pacientes de 40-59 años, que recibieron la modalidad de tratamiento combinada y con menos de 10 años de evolución.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Connors JM. Hodgkin's Lymphoma. En: Goldman L, Schafer AI, editores. Goldman's Cecil Medicine. 24a ed. New York: Elsevier Saunder; 2012. p. 1228-33.

2. Eichenauer DA, Engert A, Diehl V. Hodgkin Lymphoma: clinical manifestations, staging, and therapy. En: Hoffman R, Benz EJ, Leslie E. Silberstein LE, editores. Hematology: Basic Principles and Practice. 6a ed. Philadelphia: Elsevier Saunder; 2013. p. 1138-56.

3. Provencio M, Millán I, España P, Sánchez AC, Sánchez JJ, Cantos B, et al. Analysis of competing risks of causes of death an their variation over different time periods in Hodgkin's Disease. Clin Cancer Res. 2008;14:5300-5.

4. Goodman KA, Riedel E, Serrano V, Gulatin S, Moskowitz C,Yahalom J. Long-term effects of High dose chemotherapy and radiation for relapsed and refractary Hodgkin´s lymphoma. J Clin Oncology. 2008;26:5240-7.

5. Swerdlow A, Higgins C, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin´s disease. J Nat Cancer Inst. 2007;99:206-14.

6. Dores GM, Cote TR, Travis LB. New malignancies following Hodgkin lymphoma, non Hodgkin lymphoma and myeloma in SEER Cancer Registries. Nat Cancer Inst. 2006;5:5302-8.

7. Hodgson D, Gilbert E, Dores G, Schonfeld S, Lynch Ch, Storm H, et al. Long-term solid cancer risk among 5 years survivors of Hodgkin´s disease. J Clin Oncology. 2007;25:1489-97.

8. Castellino SM, Geiger AM, Mertens AC, Tooze JA, Goodman P, Stovall M, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806-16.

9. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematology. 2012;87:1096-103.

10. Ng AK, Chi R, Li S, Neuberg D, Fisher DC, Silver B, et al. A prospective study of pulmonary function in Hodgkin´s lymphoma patients. Ann Oncology. 2008;19:1754-8.

11. Aleman BM, Van Leeuwen FE, Klokman WJ, Van den Belt-Dusbout AW, Van t Veer MB, Bartelink H, et al. Long-term cause specific mortality of patients treated for Hodgkin's disease. J Clin Oncology. 2003;21:3431-9.

12. Thompson CA, Mauch K, Havyer R, Bhagra A, Kalsi H, Hayes SN, et al. Care of the adult Hodgkin's lymphoma survivor. Am J Med. 2011;124:1106-12.

13. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, De Braun M, van ´t Veer M, Baaijens M, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-86.

14. Meyer RM, Hoppe TR. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Hematology Am Soc Hematol Educ Program. 2012; 2012:313-21.

15. Armitage JO. Early-Stage Hodgkin's Lymphoma. N Engl J Med. 2010;363:653-62.

16. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. J Clin Oncology. 2011;29:4096-104.

17. Straus DJ. Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult Hodgkin lymphoma patient. Ther Adv Hematol. 2011;2:111-9.

18. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncology. 2002;20:3484-94.

19. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncology. 2002;20:2101-08.

20. Hodgson DC. Late Effects in the Era of Modern Therapy for Hodgkin Lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:323-9.

21. Crump M, Hodgson D. Secondary breast cancer in Hodgkin´s Lymphoma survivors. J Clin Oncology. 2009;27:4229-31.

22. Veit-Rubin N, Rapiti E, Usel M, Benhamou S, Vinh-Hung V, Vlastos G, et al. Risk, Characteristics, and Prognosis of Breast Cancer after Hodgkin's Lymphoma. The Oncologist. 2012;17:783-91.

23. Meyer R, Gospodarowicz M, Connors JM, Pearcey R, Bezjak A, Wells W, et al. Randomized comparison of ABVD chemotherapy with a strategy that incluyes radiation therapy in patients with limited stage Hodgkin´s Lymphoma: National Cancer Institute of Canada Clinical Trials Groupand the Eastern Cooperative Oncology Group. J Clin Oncology. 2005;23:4634-42.

24. Herbs C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin´s lymphoma: a systematic rewiew. Haematologica. 2009;95:494-500.

25. Franklin J, Pluetschow A, Paus M, Specht L, Aviles A, Biti G, et al. Second malignancy risk associated with treatment of Hodgkin´s lymphoma: meta- analysis of the randomized trials. Ann Oncology. 2006;17:1749-60.

26. Omer B, Kadan-Lottick NS, Roberts KB, Wang R, Demsky C, Kupfer GM, et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematology. 2012;158:615-25.

27. De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes. J Clin Oncology. 2009;27:4239-46.

28. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematology. 2011;154:23-30.

29. Dunleavy K, Bollard CM. Sobering realities of surviving Hodgkin Lymphoma. Blood. 2011;117:1772-3.

30. Barbaro PM, Johnston K, Dalla-Poza L, Cohn RJ, Wang YA, Marshall GM, et al. Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy. Ann Oncol. 2011;22:2569-74.

31. Straus DJ, Portlock Carol S. Resultsof a prospective randomized clinical trial of doxorubicin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483-9.

32. Sieniawski M, Reineke T, Nogova L, Jostin GA, Pfistner B, Diehl V, et al. Fertility in male patients with advanced Hodgkin lymphomatreated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111:71-76.

33. Ferme C, Eghbali H, Meerwaldt JH. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New Eng J Med. 2007;357:1916-27.

34. Dabaja B, Cox JD, Buchhols TA. Radiation therapy can still be used safely in combined modality approaches in patients with Hodgkin's lymphoma. J Clin Oncology. 2007;25:3-5.

35. Huang MD, Xiaoxue MD, Jennifer MR, Rikka S, Kim L, Lee Y, et al. Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice. Circu Ame Heart Ass. 2010;121:615-6.